A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype

American Journal of Respiratory Cell and Molecular Biology

Volumn 41, Issue 2, 2009, Pages 217-225

  Norez, Caroline ^a   Antigny, Fabrice ^a   Noel, Sabrina ^a   Vandebrouck, Clarisse ^a   Becq, Frédéric ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Calcium homeostasis; Epithelial Na+ channel; F508del cystic fibrosis transmembrane conductance regulator; Miglustat; Sodium hyperabsorption

Indexed keywords

CALCIUM; CHLORIDE CHANNEL; MIGLUSTAT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CALCIUM HOMEOSTASIS; CYSTIC FIBROSIS; GENE MUTATION; HUMAN; HUMAN CELL; LONG TERM CARE; PROTEIN TRANSPORT; REGULATORY MECHANISM; RESPIRATORY EPITHELIUM; SODIUM ABSORPTION;

1-DEOXYNOJIRIMYCIN; ANIMALS; CALCIUM; CELL LINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME INHIBITORS; EPITHELIAL CELLS; EPITHELIAL SODIUM CHANNEL; HOMEOSTASIS; HUMANS; MICE; PATCH-CLAMP TECHNIQUES; PHENOTYPE; RESPIRATORY MUCOSA;

EID: 67651152728     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0285OC     Document Type: Article

References (30)

1. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79:S23-S45.
2. Kopito RR. Biosynthesis and degradation of CFTR. Physiol Rev 1999;79:S167-S173.
3. Heda GD, Tanwani M, Marino CR. The delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 2001;280:C166-C174.
4. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991;354:526-528.
5. Kunzelmann K, Mall M. Pharmacotherapy of the ion transport defect in cystic fibrosis. Clin Exp Pharmacol Physiol 2001;28:857-867.
6. Mall M, Kunzelmann K. Correction of the CF defect by curcumin: hypes and disappointments. Bioessays 2005;27:9-13.
7. Zeitlin PL. Future pharmacological treatment of cystic fibrosis. Respiration 2000;67:351-357.
8. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007;13:231-240.
9. Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, Melin P, DeJonge H, Becq F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006;580:2081-2086.
10. Antigny F, Norez C, Becq F, Vandebrouck C. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium 2008;43:175-183.
11. Noel S, Wilke M, Bot AG, De Jonge HR, Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008;325:1016-1023.
12. Egan ME, Glockner-Pagel J, Ambrose C, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibel J, et al. Calciumpump inhibitors induce functional surface expression of delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002;8:485-492.
13. Lipecka J, Norez C, Bensalem N, Baudouin-Legros M, Planelles G, Becq F, Edelman A, Davezac N. Rescue of deltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network. J Pharmacol Exp Ther 2006;317:500-505.
14. 2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 2006;7:562-573.
15. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100:2457-2465.
16. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-490.
17. Wang Y, Loo TW, Bartlett MC, Clarke DM. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 2007;71:751-758.
18. Jefferson DM, Valentich JD, Marini FC, Grubman SA, Iannuzzi MC, Dorkin HL, Li M, Klinger KW, Welsh MJ. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am J Physiol 1990;259:L496-L505.
19. Norez C, Heda GD, Jensen T, Kogan I, Hughes LK, Auzanneau C, Derand R, Bulteau-Pignoux L, Li C, Ramjeesingh M, et al. Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods. J Cyst Fibros 2004;3:119-121.
20. Norez C, Pasetto M, Dechecchi MC, Barison E, Anselmi C, Tamanini A, Quiri F, Cattel L, Rizzotti P, Dosio F, et al. Chemical conjugation of fDeltagF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue CĨ channel functions. Am J Physiol Lung Cell Mol Physiol 2008.295:L336-L347.
21. Dall'Asta V, Gatti R, Orlandini G, Rossi PA, Rotoli BM, Sala R, Bussolati O, Gazzola GC. Membrane potential changes visualized in complete growth media through confocal laser scanning microscopy of bis-oxonol-loaded cells. Exp Cell Res 1997;231:260-268.
22. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glockner-Pagel J, Canny S, Du K, Lukacs GL, Caplan MJ. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004;304:600-602.
23. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al. Rescue of deltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
24. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of deltaF508-CFTR. Am J Physiol Cell Physiol 2000;278:C259-C267.
25. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes deltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 2001;281:L58-L68.
26. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. Small-molecule correctors of defective deltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-2571.
27. Delisle BP, Anderson CL, Balijepalli RC, Anson BD, Kamp TJ, January CT. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C. J Biol Chem 2003;278:35749-35754.
28. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, et al. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica 2006;91:703-706.
29. Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica 2007;37:298-314.
30. McCormack PL, Goa KL. Miglustat. Drugs 2003;63:2427-2434.